Table 3.

Association between circulating DBP concentration and risk of renal cell carcinoma in the CPS-II cohort

Q1Q2Q3Q4
(<272 μg/mL)(272–<294 μg/mL)(294–<334 μg/mL)(≥334 μg/mL)Ptrend
#Cases/#controls28/2229/2217/2213/21
OR (95% CI)a1.0 (ref)0.86 (0.40–1.88)0.42 (0.16–1.12)0.29 (0.09–0.91)0.02
OR (95% CI)b1.0 (ref)0.93 (0.41–2.11)0.42 (0.15–1.15)0.33 (0.10–1.06)0.03
OR (95% CI)c1.0 (ref)0.98 (0.42–2.31)0.39 (0.14–1.08)0.36 (0.11–1.22)0.048
OR (95% CI)d1.0 (ref)1.00 (0.42–2.38)0.36 (0.13–1.05)0.33 (0.09–1.16)0.041
  • aConditioned on matching factors (age, sex, race, date of blood collection).

  • bConditioned on matching factors (age, sex, race, date of blood collection); additionally adjusted for BMI.

  • cConditioned on matching factors (age, sex, race, date of blood collection); additionally adjusted for BMI, supplemental vitamin D use, and family history of any cancer.

  • dConditioned on matching factors (age, sex, race, date of blood collection); additionally adjusted for BMI, supplemental vitamin D use, family history of any cancer, and smoking status.